GLP-1 (SG) 5mg

Specification

What does the research on GLP-1 (SG) investigate?

GLP-1 (SG) is a thirty-one residue analogue of glucagon-like peptide-1, and it is one of the clearest examples in this catalogue of a sequence engineered for persistence rather than for novelty. Three substitutions in the backbone resist the enzyme that would otherwise degrade it quickly, and a fatty diacid chain attached through a linker to a lysine gives it an albumin-binding handle, so the molecule spends far longer in circulation than the parent hormone. Both changes are visible analytically. The backbone substitutions alter mass and retention, and the lipid chain makes the molecule markedly more hydrophobic and shifts it late on a reversed-phase column. Identity confirmation has to establish both that the sequence is right and that the lipid is attached. Nothing here describes a use, benefit, dose or effect in people.

Is GLP-1 (SG) legal in the UK?

Semaglutide is a licensed prescription medicine in the United Kingdom and many other countries when presented for human use. The material listed here is not that product, is not licensed for any use, and is not supplied for human use. It is offered strictly as a research chemical for in-vitro laboratory work, and that framing is what makes the listing lawful rather than any property of the molecule.

Three pieces of legislation frame that distinction. The Human Medicines Regulations 2012 make it an offence to sell an unlicensed product for human use. The Psychoactive Substances Act 2016 prohibits supplying a psychoactive substance for human consumption, which is why a research-only basis is not a formality. The Misuse of Drugs Act 1971 would apply only if the compound were scheduled, and it is not. Each of these turns on the purpose of the supply, so the statements on this page are written plainly rather than tucked into small print.

In practice that means a supplier may lawfully sell to a researcher, research organisation or business buying for research, and the buyer confirms at checkout that they are 18 or over, buying in the course of research, and responsible for handling, storing and disposing of the material lawfully. Nothing here is legal advice for your own circumstances; if you need a position, take qualified advice.

The material listed here is not that product, is not licensed for any use, and is not supplied for human use.

How are identity and quality assured?

Each released lot is tested and the result is published, rather than the material being described as high purity on the strength of a supplier's word. Purity is measured by reversed-phase HPLC at an independent laboratory. The laboratory used for every lot published so far is Janoshik Analytical, in the Czech Republic, and the result is stated alongside the measured content against label so the two can be read together.

The report carries the lot number printed on the vial, which is the part that matters. A certificate showing a result without a lot number cannot be tied to the vial in front of you, and a certificate for a different lot tells you nothing about yours. Matching the printed number on the label to the number on the report is a five second check and it is the whole point of publishing both.

Identity confirmation by mass spectrometry is a separate test and is ordered as an add-on, so the figures published here come from RP-HPLC purity testing unless a report says otherwise. Where no report is published for a listing yet, the documentation held for the lot being shipped can be requested before you order. We would rather send you what exists than let you assume a certificate is available when it is not.

Synthesis and supply

Peptide material is built by solid-phase synthesis, purified by preparative HPLC, then lyophilised. Lyophilisation freezes the solution and removes the solvent under vacuum, which is why the vial arrives holding a cake or powder rather than a liquid and why a solvent has to be added before the material can be worked with. Removing water also removes the main route by which a peptide degrades in storage, which is the reason the format is used.

Sequence length and modification are what make batches differ in difficulty. Every coupling step is an opportunity for a truncated or deleted by-product, and a heavily modified or long chain presents more of them, which is why the purity trace rather than the headline figure is what a certificate is read for. Vials are filled and labelled with the lot number, and the lot number is what the report and the verification lookup resolve against.

The lipid side chain is attached through a linker in a dedicated step after chain assembly, and it is the part of this molecule most likely to be missing from an otherwise correct batch.

External resources for researchers

These are the public reference sources we use when checking the identity of GLP-1 (SG), and the ones worth going to before relying on anything stated on a product page, including this one.

• PubChem — Compound records, computed properties, depositor-supplied identity data.
• CAS Common Chemistry — CAS Registry lookups where a registry number is known.
• ChEBI — Curated chemical ontology entries with cross-references.
• Europe PMC — Primary literature search by compound name, sequence or registry number.
• Certificate hub — Reports published for the lots released so far.

Frequently asked questions

Documentation & batch verification

The current released lot is IP-SEMA5-001, tested 2026-08-24 by Janoshik Analytical (CZ): RP-HPLC purity 99.789% (RP-HPLC), measured content 5.52 mg/vial, identity Purity confirmed (RP-HPLC). The full report for this lot is published and can be checked online — verify this batch. See the full record for lot IP-SEMA5-001 or all published certificates of analysis.

Published batch records show the laboratory, report date, purity and measured content where reported. Check the certificate for the exact lot: an HPLC purity result does not establish LC-MS identity, sterility or suitability for human or animal use. Review the published batch record before ordering.